聚醇消费和神经退行风险:随机对照试验的系统元分析,将营养与认知健康相结合
Xiaomei Wang1, Jiao Yang1, Jiayuan Zhang1
1Institute of Agricultural Information, Chinese Academy of Agricultural Sciences, Beijing 100081, PR China. wangxiaomei01@caas.cn.
Food & function
|January 12, 2026
概括
聚醇补充剂在神经退行性疾病 (NDD) 中显示出神经保护的前景. 黄类药物可以改善全球认知能力,而类药物可以提高日常功能,为NDD提供有针对性的营养策略.
科学领域:
- 营养神经科学 营养神经科学
- 神经保护策略 神经保护策略
- 对于NDD的饮食干预措施
背景情况:
- 神经退行性疾病 (NDD) 构成了严重的健康负担.
- 多因其潜在的神经保护性质而受到研究.
- 对于NDD中聚醇功效的证据需要进行系统的评估.
研究的目的:
- 在NDD中对多用于神经保护的临床证据进行元分析.
- 评估不同类型的多对认知和功能结果的影响.
- 评估多醇对神经精神病症状和NDD中的生物标志物的影响.
主要方法:
- 对13项涉及7个NDD的849名参与者的研究进行了元分析.
- 结果包括全球认知 (MMSE),域特定认知 (ADCS-Cog),日常生活 (ADCS-ADL),神经精神症状 (NPI) 和生物标志物 (Aβ40,BDNF).
- 遵守PRISMA 2020指南和Cochrane手册,并为证据确定性提供GRADE.
主要成果:
- 整体上,多补充剂改善了全球认知能力 (MMSE:MD=2.06).
- 黄类药物显示了适度的MMSE改善; stilbenes显著改善了日常功能 (ADCS-ADL).
- 其他多类子类和生物标志物没有显示出一致的显著影响.
结论:
- 多补充剂在NDD中为神经保护提供了潜在的好处.
- 特定的亚类,如黄类和 stilbenes 显示有选择性的认知和功能性改善.
- 有针对性的多干预措施可能是管理NDD的可行营养策略.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
535
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
535
02:59Cancer Prevention
7.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.6K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
182
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
182
01:17Oxidation of Phenols to Quinones
4.5K
In the presence of oxidizing agents, phenols are oxidized to quinones. Quinones can be easily reduced back to phenols using mild reducing agents. The electron-donating hydroxyl group enhances the reactivity of the aromatic ring, enabling oxidation of the ring even in the absence of an α hydrogen.
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
4.5K
01:30Cognitive Development During Adulthood
766
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
766
01:22Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801